Summary: Umicore

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • According to MSCI, the company's ESG score for its industry is good.

Highlights: Umicore

  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses: Umicore

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company does not generate enough profits, which is an alarming weak point.
  • The company is in debt and has limited leeway for investment
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Umicore

Source: Surperformance

ESG chart: Umicore

Source: MSCI

Fundamentals (Composite) Global Valuation (Composite) Financial estimates revisions (Composite) Capi.($)
4.03B
77.71B
45B
42.17B
25.68B
18.18B
15.01B
12.86B
10.61B
9.41B
Average 26.07B
Weighted average by Cap.
See all sector ratings
Investor (Composite)
Trader (Composite)
ESG MSCI
A

Financials

Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)

Valuation

P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield

Revisions

Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)

Business Predictability

Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence

ESG

Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-